# An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

> **NCT02848313** · PHASE1 · COMPLETED · sponsor: **Stealth BioTherapeutics Inc.** · enrollment: 40 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** Elamipretide

## Key facts

- **NCT ID:** NCT02848313
- **Lead sponsor:** Stealth BioTherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-28
- **Primary completion:** 2018-03-16
- **Final completion:** 2018-04-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02848313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02848313, "An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02848313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*